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Background: Hemodialysis patients often develop constipation due to dietary restriction and the use of phosphate
and/or potassium binders. Lubiprostone is a novel laxative that promotes defecation by activating the chloride ion
channel 2 (ClC-2) in the gastrointestinal tract. While lubiprostone has been reported to be useful in bowel control
of dialysis patients, no studies have examined changes in electrolyte levels following administration of lubiprostone.
Methods: We prospectively compared stool frequency and electrolyte levels before and after treatment with
lubiprostone in 28 hemodialysis patients treated with the drug for at least 3 months in our hospital.
Results: Mean ± standard deviation of stool frequency was significantly increased from 1.8 ± 1.3 times/week before
treatment to 4.3 ± 1.8 times/week at Month 1, 4.9 ± 1.9 times/week at Month 2, and 4.5±1.5 times/week at Month 3
(p < 0.001, p < 0.001, and p < 0.001, respectively). With regard to electrolyte levels, only serum inorganic phosphorus
(IP) level was significantly decreased, from 4.7 ± 1.5 mg/dL at baseline to 4.5 ± 1.6 mg/dL at Month 1, 4.0 ± 1.3 mg/dL at
Month 2, and 3.8 ± 1.1 mg/dL at Month 3 (p = 0.123, p < 0.001, and p < 0.001, respectively). Lubiprostone not only
improved bowel control, but also decreased serum IP levels in hemodialysis patients.
Conclusions: Lubiprostone may improve prognosis of hemodialysis patients through bowel control and a decrease in
serum IP.
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Hemodialysis patients have a higher prevalence of consti-
pation than patients with normal renal function, due to
dietary restriction, fluid restriction, and use of phosphate
and/or potassium binders [1]. Given the risk of hypermag-
nesemia due to the use of magnesium oxide preparations,
which are saline laxatives [2], hemodialysis patients often
use sennosides, which are stimulant laxatives. However,
chronic use of these compounds can result in difficulties
with bowel control due to resistance [3].
Lubiprostone is a novel laxative that promotes defecation
by activating the chloride ion channel 2 (ClC-2) on the
apical membrane of the small intestinal epithelium,
thereby increasing water secretion into the intestinal
lumen to soften feces and enhance intestinal transit.* Correspondence: shikou-gen@sayamahp.org
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lubiprostone in bowel control of dialysis patients [4],
none have examined associated changes in electrolyte
levels in these patients.
Here, we investigated changes in electrolyte levels in
hemodialysis patients after treatment with lubiprostone.Methods
Among 396 patients who underwent hemodialysis in our
hospital between August 2014 and August 2015, 44
(9 %) patients were administered lubiprostone to treat
constipation. After excluding 16 patients who dropped
out for reasons such as nausea and loss of appetite, 28
who had used the compound for at least 3 months and
gave informed consent to participate were included in
the study. This prospective observational study was ap-
proved by the Ethics Review Board of Saitama Sekishinkai
Hospital.le is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
Table 1 Baseline characteristics of patients
Number of enrolled patients
(men/women)
28 (14/14)
Age, years 69.4 ± 14.2
Duration of dialysis, years 7.7 ± 9.1
Underlying disease of renal failure Diabetic nephropathy, 11 patients
Chronic glomerulonephritis, 3 patients
Nephrosclerosis, 5 patients
Autosomal dominant polycystic kidney
disease, 1 patient
Primary hyperparathyroidism, 1 patient
Unknown, 7 patients
Concomitant laxative 17 patients
Stimulant laxative, 17 patients
Sugar laxative, 1 patient
Phosphate binder 18 patients
Calcium carbonate, 8 patients
Lanthanum carbonate, 12 patients
Bixalomer, 2 patients
Ferric citrate hydrate, 1 patient
Cinacalcet, 4 patients
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tients continued to take any oral laxatives they had
been using before treatment, with no changes in dos-
age. Lubiprostone was started at an initial dose of 24 μg
once daily after dinner and was then adjusted based on
defecation frequency. The following parameters at
months 1, 2, and 3 of treatment with lubiprostone were
compared with those before treatment (baseline): mean
weekly stool frequency; stool consistency (Bristol Stool
Form Scale); serum levels of sodium (Na), potassium
(K), corrected calcium (Ca), and inorganic phosphorus
(IP); and Geriatric Nutritional Risk Index (GNRI) for
nutritional assessment [5].Table 2 Comparison of stool and serum parameters of hemodialy
with lubiprostone
Parameter Before treatment Month 1
Mean ± SD Mean ± SD
Stool frequency (times/month) 1.8 ± 1.3 4.3 ± 1.8
Bristol Stool Form Scale 2.3 ± 1.0 3.4 ± 0.7
Serum Na (mEq/L) 137.3 ± 3.3 137.5 ± 3.0
Serum Cl (mEq/L) 102.6 ± 4.0 103.0 ± 3.0
Serum K (mEq/L) 4.4 ± 0.7 4.4 ± 0.7
Serum Ca (mg/dL) 9.2 ± 0.6 9.1 ± 0.6
Serum IP (mg/dL) 4.7 ± 1.5 4.5 ± 1.6
Geriatric nutritional risk index 85.6 ± 12.8 85.4 ± 11.9
SE standard deviation, Na sodium, Cl chloride, K potassium, Ca calcium, IP inorganicSerum levels were determined via laboratory tests per-
formed at the start of each week, and corrected Ca was
calculated using Payne’s formula. No changes were made
to any non-laxative oral drug doses or dialysis condition
throughout the study.
All data are presented as mean ± standard deviation.
The Wilcoxon signed-rank test was used to compare
two groups (continuous variables) at a significance level
of 0.05. All statistical analyses were performed using
SPSS Version 22.0 (IBM, Tokyo, Japan).Results
Baseline characteristics of patients are shown in Table 1.
A total of 28 patients (14 men and 14 women; mean age,
69.4 ± 14.2 years) were included in the study. Mean dur-
ation of dialysis was 7.7 ± 9.1 years. Underlying causes of
renal failure were diabetic nephropathy in 11 patients,
nephrosclerosis in 3, chronic glomerulonephritis in 5,
autosomal dominant polycystic kidney disease in 1, pri-
mary hyperparathyroidism in 1, and unknown in 7.
Seventeen patients had used laxatives, and 18 patients
had used phosphate binders (e.g., calcium carbonate,
lanthanum carbonate) and/or cinacalcet.
After starting treatment with lubiprostone at an initial
dose of 24 μg, the dose level was increased to 48 μg in
two divided doses per day after breakfast and dinner in
10 patients due to poor bowel control. Results at base-
line and months 1, 2, and 3 of treatment are shown in
Table 2. Stool frequency was significantly increased from
1.8 ± 1.3 times/week at baseline to 4.3 ± 1.8 times/week
at month 1, 4.9 ± 1.9 times/week at month 2, and 4.5 ± 1.5
times/week at month 3 (p < 0.001, p < 0.001, and p < 0.001,
respectively). The Bristol Stool Form Scale score was sig-
nificantly increased from 2.3 ± 1.0 at baseline to 3.4 ± 0.7
at month 1, 3.5 ± 0.8 at month 2, and 3.6 ± 0.6 at month 3
(p < 0.001, p < 0.001, and p < 0.001, respectively). While no
significant changes were noted in serum Na, Cl, K, orsis patients before and 1, 2, and 3 months after treatment
Month 2 Month 3
p value Mean ± SD p value Mean ± SD p value
p < 0.001 4.9 ± 1.9 p < 0.001 4.5 ± 1.5 p < 0.001
p < 0.001 3.5 ± 0.8 p < 0.001 3.6 ± 0.6 p < 0.001
p = 0.963 138.2 ± 3.5 p = 0.070 138.2 ± 4.0 p = 0.180
p = 0.434 103.1 ± 3.6 p = 0.504 103.0 ± 3.2 p = 0.743
p = 0.873 4.3 ± 0.6 p = 0.415 4.3 ± 0.6 p = 0.626
p = 0.159 9.2 ± 0.6 p = 0.608 9.2 ± 0.6 p = 0.499
p = 0.123 4.0 ± 1.3 p < 0.001 3.8 ± 1.1 p < 0.001
p = 0.501 86.2 ± 11.9 p = 0.220 86.4 ± 11.1 p = 0.061
phosphorus
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the serum IP level was significantly decreased from 4.7 ±
1.5 mg/dL at baseline to 4.5 ± 1.6 mg/dL at month 1, 4.0 ±
1.3 mg/dL at month 2, and 3.8 ± 1.1 mg/dL at month 3 (p
= 0.123, p < 0.001, and p < 0.001, respectively). No signifi-
cant changes were noted in GNRI between baseline
and month 1, 2, or 3.
Discussion
This study showed that lubiprostone not only improved
bowel control but also decreased serum IP levels in
hemodialysis patients.
Hemodialysis patients have a high prevalence of con-
stipation due to dietary restriction, fluid restriction, and
use of phosphate binders [1]. It has been reported that
constipation is associated with an increased risk of death
from cardiovascular disease (CVD) [6], suggesting the
importance of bowel control in dialysis patients, who
have a high risk of death from CVD [7]. Lubiprostone is
a novel laxative that promotes defecation by activating
ClC-2 on the apical membrane of the small intestinal
epithelium, thereby increasing water secretion into the
intestinal lumen to soften feces and enhance intestinal
transit. In the present study, lubiprostone increased the
mean weekly stool frequency and the Bristol Stool Form
Scale score, showing its usefulness in bowel control of
dialysis patients.
Lubiprostone decreased serum IP levels in hemodialysis
patients. A report evaluating the safety of lubiprostone
in patients with chronic constipation found no change
in serum electrolytes, including Na, K, and Cl, before
and after administration, although serum IP values
were not measured [8]. In a study in mice, urinary
toxins including BUN, indoxyl sulfate, and hippurate
were reported to decrease with lubiprostone admin-
istration [9], which the authors speculated was due
to lubiprostone-induced recovery of imbalances in
the gut microbiota. The decrease in serum IP values
in our study might have involved similar effects.
Alternatively, the decrease might have been due to
improved adherence to oral phosphate binders
associated with improved bowel control following
administration of lubiprostone, albeit that the oral
intake of phosphorus adsorption drugs before and
after lubiprostone administration was not confirmed.
Decreased food intake and/or nutritional status due
to nausea and/or anorexia caused by lubiprostone
might also have been responsible for the decrease in
serum IP, but this is implausible given the lack of
change from baseline in GNRI after treatment with
lubiprostone.
Since it has been reported that constipation was asso-
ciated with an increased risk of death from CVD [6],
bowel control may decrease the risk of death from CVDin dialysis patients. In addition, hyperphosphatemia
not only induces secondary hyperparathyroidism and
related abnormal bone metabolism but also increases
the risk of cardiovascular complications and death
through vascular calcification [10]. Serum IP control
is therefore recommended to improve prognosis [11].
As such, lubiprostone may improve long-term life
prognosis if it is indeed effective in controlling serum
IP levels.
Several limitations of the present study warrant men-
tion. First, our study was not designed to compare treated
and untreated patients, as all patients received lubipros-
tone. Second, the study was a small, single-center study
with a short follow-up. A definitive conclusion on the util-
ity of lubiprostone in hemodialysis patients will require
larger, longer-term studies.
Conclusions
Lubiprostone not only improved bowel control but
also decreased serum IP levels in hemodialysis patients.
Lubiprostone may improve the prognosis of hemodialysis
patients by improving bowel control and decreasing
serum IP.
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